TOP1210

TOP1210 is a small molecule narrow-spectrum kinase inhibitor (NSKI) developed for the treatment of inflammatory bowel diseases (IBD), specifically ulcerative colitis. It acts by simultaneously inhibiting three key signaling nodes: p38α mitogen-activated protein kinase (MAPK), Src family kinases (SFK), and spleen tyrosine kinase (Syk). This multikinase approach is designed to overcome the redundancy in inflammatory signaling pathways that often limits the clinical efficacy of highly selective kinase inhibitors. TOP1210 is intended for topical delivery to the gastrointestinal tract to maximize local anti-inflammatory activity at the site of mucosal inflammation while minimizing systemic exposure and associated off-target toxicities.